1. Home
  2. VSME vs ZNTL Comparison

VSME vs ZNTL Comparison

Compare VSME & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VSME
  • ZNTL
  • Stock Information
  • Founded
  • VSME 2013
  • ZNTL 2014
  • Country
  • VSME Hong Kong
  • ZNTL United States
  • Employees
  • VSME 46
  • ZNTL N/A
  • Industry
  • VSME
  • ZNTL Biotechnology: Pharmaceutical Preparations
  • Sector
  • VSME
  • ZNTL Health Care
  • Exchange
  • VSME Nasdaq
  • ZNTL Nasdaq
  • Market Cap
  • VSME 103.9M
  • ZNTL 105.8M
  • IPO Year
  • VSME 2023
  • ZNTL 2020
  • Fundamental
  • Price
  • VSME $2.28
  • ZNTL $1.55
  • Analyst Decision
  • VSME
  • ZNTL Buy
  • Analyst Count
  • VSME 0
  • ZNTL 6
  • Target Price
  • VSME N/A
  • ZNTL $6.53
  • AVG Volume (30 Days)
  • VSME 2.4M
  • ZNTL 689.2K
  • Earning Date
  • VSME 04-14-2025
  • ZNTL 11-11-2025
  • Dividend Yield
  • VSME N/A
  • ZNTL N/A
  • EPS Growth
  • VSME N/A
  • ZNTL N/A
  • EPS
  • VSME N/A
  • ZNTL N/A
  • Revenue
  • VSME $8,248,108.00
  • ZNTL $26,865,000.00
  • Revenue This Year
  • VSME N/A
  • ZNTL N/A
  • Revenue Next Year
  • VSME N/A
  • ZNTL N/A
  • P/E Ratio
  • VSME N/A
  • ZNTL N/A
  • Revenue Growth
  • VSME 3.22
  • ZNTL N/A
  • 52 Week Low
  • VSME $0.51
  • ZNTL $1.01
  • 52 Week High
  • VSME $3.69
  • ZNTL $4.44
  • Technical
  • Relative Strength Index (RSI)
  • VSME 43.87
  • ZNTL 49.14
  • Support Level
  • VSME $2.11
  • ZNTL $1.47
  • Resistance Level
  • VSME $2.68
  • ZNTL $1.69
  • Average True Range (ATR)
  • VSME 0.32
  • ZNTL 0.10
  • MACD
  • VSME -0.11
  • ZNTL 0.00
  • Stochastic Oscillator
  • VSME 17.08
  • ZNTL 53.57

About VSME VS Media Holdings Limited

VS Media Holdings Ltd manages a network of digital Creators who create and publish content to social media platforms such as YouTube, Facebook, Instagram, and TikTok. Its Creators include influencers, KOLs-Key Opinion Leaders, bloggers, and other content creators who cultivate fan bases on social media platforms. The company's business provides value to two business stakeholders: Creators and Brands. The Value to Creators, that empowers and supports Creators by providing them with production facilities, training, and funding to produce quality content and the Value to Brands, where the company bridges the divide between Brands and Creators by helping Brands reach their target audience effectively by advising on content and budget and recommending specific Creators.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: